In a nutshell This article reviewed current treatment options for treating multiple myeloma (MM). Some background MM is a form of cancer that originates from plasma cells (a form of white blood cell). This usually results in other normal cells of the bone marrow not working properly. MM is usually diagnosed in older patients. Despite...
Read More
In a nutshell This study looked at the effect statins had on the outcomes of patients with multiple myeloma (MM). The authors found that the use of statins is likely associated with lower mortality in these patients. Some background MM is a form of cancer that originates from plasma cells (a form of white blood cell). This usually results...
Read More
In a nutshell This trial is aiming to examine the effectiveness of combination therapy with venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Ozurdex) with or without bortezomib (Velcade) for unresponsive or relapsed multiple myeloma (MM). The main outcome that is to be measured is the response rate, time to response,...
Read More
In a nutshell This study investigated the impact of the D-Rd regimen including daratumumab (Darzalex) combined with lenalidomide (Revlimid) and dexamethasone (Decadron) on the quality of life of patients with multiple myeloma (MM) who cannot undergo a transplant. The study showed that patients who received D-Rd reported lower levels of...
Read More
In a nutshell This study evaluated the treatment schedule for panobinostat (Farydak) tablets combines with subcutaneous (injections under the skin) bortezomib (Velcade) and dexamethasone (Ozurdex) tablets in patients with relapsed/refractory (R/R) multiple myeloma (MM). The study found that 20mg of panobinostat should be given twice...
Read More
In a nutshell This study was carried out to examine the effectiveness of autologous stem cell transplant (ASCT) in the management of older patients with multiple myeloma (MM). The authors concluded that ASCT was an effective consolidation therapy in patients with MM across all age groups. Some background MM is a more commonly a cancer of older...
Read More
In a nutshell The authors looked at the use of busulfan (Myleran), melphalan (Alkeran), and bortezomib (Velcade) compared with melphalan only for autologous stem cell transplantation (autoSCT) in the treatment of multiple myeloma (MM). The authors concluded that using this drug combination leads to an...
Read More
In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment. This study concluded that this treatment combination was effective in...
Read More
In a nutshell This study investigated if giving patients with aggressive multiple myeloma (MM) a combination of selinexor (Xpovio), bortezomib (Velcade), and dexamethasone (Ozurdex) could improve their survival. The study suggested that this combination improved patients’ outcomes. Some background Multiple Myeloma (MM) is an...
Read More
In a nutshell This study investigated whether giving patients with relapsed/resistant multiple myeloma (MM) venetoclax (Venclexta), in combination with bortezomib (Velcade) and dexamethasone (Ozurdex), will improve patient survival. This study showed that these patients would benefit from this treatment combination. Some background...
Read More
In a nutshell This study was carried out to determine whether early stem cell transplant (SCT) or a delayed SCT improved the survival of patients with multiple myeloma (MM). The study found that there was no significant difference in survival in patients with newly diagnosed MM who received early or late SCT. Some background SCT is an...
Read More
In a nutshell The study compared outcomes of once-weekly (OW) versus twice-weekly (TW) carfilzomib (Kyprolis) plus dexamethasone (Decadron) in Japanese patients with relapsed/refractory (RR) multiple myeloma (MM). The authors found that the OW dosage improved overall response rate (ORR) compared to TW in such patients. Some background RR-MM...
Read More
